Ultrasound-augmented cancer immunotherapy

Liu, Bingjie; Du, Fangxue; Feng, Ziyan; Xiang, Xi; Guo, Ruiqian; Ma, Lang; Zhu, Bihui; Qiu, Li

doi:10.1039/d3tb02705h

Cited by 5 publications

(1 citation statement)

References 109 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…20–24 Besides, SDT utilizes sonosensitizers to generate ROS via the sonodynamic effect under ultrasound (US) irradiation. 25–27 Similar to PDT, SDT has been reported to have slight toxicity to adjacent normal tissues and thus widely used for tumor ablation. 28–31 In addition, because US penetrates deeply into the tumor tissues, SDT can overcome the tissue penetration depth limitations.…”

Section: Introductionmentioning

confidence: 99%

Radioactive hybrid semiconducting polymer nanoparticles for imaging-guided tri-modal therapy of breast cancer

Gu,

Cheng,

et al. 2024

J. Mater. Chem. B

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Radioactive hybrid semiconducting polymer nanoparticles for imaging-guided tri-modal therapy of breast cancer

Gu,

Cheng,

et al. 2024

J. Mater. Chem. B

View full text Add to dashboard Cite

show abstract

A Highly Potent Os@Au‐TPA Coordination Structure‐Based Sonosensitizer for Tumor Sono‐Immunotherapies

Xie,

Rong,

Qin

et al. 2024

Adv Funct Materials

View full text Add to dashboard Cite

Ultrasound (US) becomes an appealing modality for stimulating or amplifying immune responses during cancer therapy, which is also termed sono‐immunotherapy. However, the clinical prospect has not been fully realized due to the scarcity of efficient sonosensitizers. Herein, for the first time a novel Os‐doped Au‐tri(pyridin‐4‐yl) amine coordination structure (Os@Au‐TPA)‐based sonosensitizer is originally designed and synthesized for sono‐immunotherapy of breast‐metastasized tumors. Impressively, Os@Au‐TPA shows much higher US‐mediated 1O2‐producing activity than Au‐TPA as well as the other traditional sonosensitizers, for example, ≈41.6 folds to ce6, 19.5 times to Protoporphyrin IX (PpIX), 12.0 to Indocyanine Green (ICG), and 11.1 to Iron phthalocyanine (Pc(Fe)). The Os@Au‐TPA can not only generate abundant ROS upon US irradiation to implement sonodynamic therapy (SDT), stimulating cell apoptosis and further immunogenic cell death, but can also generate O2 to alleviate hypoxia to promote the polarization of M2 to M1 macrophages to enhance tumor immunogenicity. As a result, when combined with PD‐L1 antibody, it remodels the immunosuppressive tumor microenvironment, achieves concurrent sonodynamic‐triggered immune activation, and eradicates both the original and distant‐metastasized tumors efficiently. This work not only provides a new strategy to construct potent sonosensitizers from pyridine‐metal coordination structures but also proves that sonosensitizers with high performance are crucial in boosting cancer sono‐immunotherapy.

show abstract

Implantable Biomaterials for Cancer Immunotherapies

Pechnikova,

Aggeli,

Latypova

et al. 2024

Adv Funct Materials

View full text Add to dashboard Cite

Cancer immunotherapy has revolutionized cancer treatment by leveraging the immune system to target and eliminate tumor cells. Implantable biomaterials, such as hydrogels, sponges, scaffolds, implantable microdevice platforms, and macrobeads, offer localized and sustained release of immunomodulatory agents, improving the delivery of treatments such as immune checkpoint inhibitors, cancer vaccines, and adoptive cell therapies like CAR‐T cells. This review examines the emerging role of these biomaterials in modulating the tumor microenvironment, enhancing immune cell recruitment, and reducing systemic side effects, positioning them as significant tools for treating solid tumors. Recent advances in material engineering are also discussed, including the integration of bioactive molecules and real‐time therapeutic adjustments based on patient‐specific immune responses, which offer new potential in personalized cancer treatments. However, challenges such as biocompatibility, high production costs, variability in patient response, and the necessity of surgical manipulations remain key obstacles. Nonetheless, ongoing research and technological advancements are steadily addressing these issues, paving the way for more effective and accessible cancer immunotherapies. Overall, this review highlights the promise of implantable biomaterials overcoming the current limitations of cancer immunotherapy and expanding the scope of effective, targeted cancer treatments.

show abstract

Ultrasound-augmented cancer immunotherapy

Abstract: Cancer remains a growing worldwide health problem with the most broadly studied treatments, in which immunotherapy has made notable advancements during the recent years. However, innumerable patients have presented the...

Cited by 5 publications

References 109 publications

Radioactive hybrid semiconducting polymer nanoparticles for imaging-guided tri-modal therapy of breast cancer

Radioactive hybrid semiconducting polymer nanoparticles for imaging-guided tri-modal therapy of breast cancer

A Highly Potent Os@Au‐TPA Coordination Structure‐Based Sonosensitizer for Tumor Sono‐Immunotherapies

Implantable Biomaterials for Cancer Immunotherapies

Contact Info

Product

Resources

About